What You Should Know
- The Raise: Synchrony Medical, a respiratory care technology company, has closed an oversubscribed $5M funding round led by Edge Medical Ventures.
- The Tech: The company’s FDA-cleared device, LibAirty™, is a wearable airway clearance system designed for home use. Clinical data shows it can clear twice as much sputum as conventional therapies.
- The Growth: The funding—which includes backing from the NJEDA—will support the commercial expansion of the device in the U.S. and scale operations at its Jersey City headquarters.
The “Twice as Effective” Claim
The standout statistic in Synchrony’s pitch is clinical efficacy. Standard airway clearance usually involves a vest that vibrates the chest wall (HFCWO). It is loud, bulky, and often uncomfortable. Synchrony claims that LibAirty is not only more comfortable but clinically superior, citing data that it clears “twice as much sputum” as conventional therapies.
In respiratory care, sputum volume is the gold standard metric. If you can get more mucus out of the lungs, you drastically reduce the risk of pneumonia and hospitalization.
The Jersey Connection
The round included participation from the New Jersey Economic Development Authority (NJEDA) through the New Jersey Innovation Evergreen Fund. This is a strategic win for the state’s life sciences sector. Synchrony will continue to expand its operations from its Jersey City headquarters, solidifying the region as a hub for medtech innovation.
